# Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)

> **NCT00799773** · PHASE3 · TERMINATED · sponsor: **Carelon Research** · enrollment: 3 (actual)

## Conditions studied

- Thrombotic Thrombocytopenic Purpura

## Interventions

- **DRUG:** Rituximab
- **PROCEDURE:** Plasma exchange
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT00799773
- **Lead sponsor:** Carelon Research
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Low enrollment rate
- **Last updated:** 2013-07-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00799773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00799773, "Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00799773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*